Amivantamab plus lazertinib shows survival benefit in lung cancer

Janssen drug combination extends life expectancy during trial

Janssen-Cilag International NV has announced results from the phase 3 MARIPOSA study, demonstrating a significant overall survival benefit for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC). The study compared Rybrevant (amivantamab) plus Lazcluze (lazertinib) to osimertinib as a first-line treatment.

The data, presented at the 2025 European Lung Cancer Congress, showed that the amivantamab plus lazertinib combination significantly extended overall survival compared to osimertinib.

Median overall survival for the combination therapy has not yet been reached, and projections suggest an improvement of more than one year compared to osimertinib’s median of 36.7 months.

Professor Nicolas Girard, trial investigator, said: “The survival curve demonstrates that amivantamab plus lazertinib can help patients live longer compared to osimertinib monotherapy, and suggests the benefit keeps growing over time.

“We see the gap between the survival curves continue to widen, which is exactly what we want to see in lung cancer treatment to improve outcomes for patients. These results reinforce that we are entering a new era for EGFR-mutated advanced non-small cell lung cancer.”

The study also showed that the combination therapy prolonged secondary endpoints, including intracranial progression-free survival and time to symptomatic progression. The safety profile of amivantamab plus lazertinib was consistent with previous analyses, with manageable adverse events.

Henar Hevia, PhD, Senior Director, EMEA Therapeutic Area Lead, Oncology, Johnson & Johnson Innovative Medicine, said: “We are committed to redefining the standard of care for people living with lung cancer and are excited to be at a point where that is becoming a reality.

The overall survival results from the MARIPOSA study reinforce the potential life-changing impact the chemotherapy-free combination of amivantamab and lazertinib can have for patients and their loved ones, when used in the first-line setting.”

The MARIPOSA study met its primary endpoint in October 2023, demonstrating a statistically significant improvement in progression-free survival compared to osimertinib.